Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02276443 · ClinicalTrials.gov registry record · NA
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
A NA study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 798
- Enrollment target
- 5
- Study locations
NCT02276443 is a NA study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 798 participants, above the 467-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (71% higher). The trial reports 5 study locations across 1 state.
The verdict
NCT02276443, a NA study of Invasive Breast Carcinoma and Stage II Breast Cancer AJCC v6 and v7, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 798 participants
- Enrollment target
- 5
- Study locations
Study Summary
This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed treatment trial can improve the responses in patients with newly diagnosed triple-negative breast cancer (TNBC). Testing the primary tumor biopsy for certain proteins and monitoring the lymphocyte infiltration into the tumors may help doctors determine the sub-type of TNBC, and direct treatments that may work well. It is not yet known whether assigning treatment based on the patient's tumor classification will improve how well the tumor responds.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Chemotherapy
- OTHER Immunotherapy
- PROCEDURE Ultrasonography
- PROCEDURE Lymph Node Biopsy
Study Locations (5)
Texas
- MD Anderson in The Woodlands - Conroe
- M D Anderson Cancer Center - Houston
- MD Anderson West Houston - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 798 participants |
| Start Date | 2015-11-09 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02276443
The ClinicalTrials.gov registry entry for NCT02276443 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 798 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 467-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (71% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02276443 reports 5 study locations spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02276443 about?
NCT02276443 is a clinical study titled "Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative". This clinical trial assesses whether a newly designed algorithm which looks at the genomic signature of each patient's tumor to predict their sensitivity to standard of care treatment verses being placed on a personally designed treatment trial can improve the responses in patients with newly diagno...
What is the current status of trial NCT02276443?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 798 participants. The study started on 2015-11-09. Estimated completion is 2026-11-30.
What conditions does trial NCT02276443 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7.
What interventions are being tested in trial NCT02276443?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Chemotherapy (DRUG), Immunotherapy (OTHER), Ultrasonography (PROCEDURE), Lymph Node Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02276443?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02276443 being conducted?
This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
RECRUITING · NA
-
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
RECRUITING · NA
-
Neoadjuvant Breast Cancer Time Restricted Eating
RECRUITING · NA
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer
ACTIVE NOT RECRUITING · NA
-
Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.